IL291197A - Phospholipid ether conjugates as vehicles for cancer-targeting drugs - Google Patents
Phospholipid ether conjugates as vehicles for cancer-targeting drugsInfo
- Publication number
- IL291197A IL291197A IL291197A IL29119722A IL291197A IL 291197 A IL291197 A IL 291197A IL 291197 A IL291197 A IL 291197A IL 29119722 A IL29119722 A IL 29119722A IL 291197 A IL291197 A IL 291197A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- targeting drug
- phospholipid ether
- drug vehicles
- ether conjugates
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000003904 phospholipids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899615P | 2019-09-12 | 2019-09-12 | |
| US201962899611P | 2019-09-12 | 2019-09-12 | |
| US201962899618P | 2019-09-12 | 2019-09-12 | |
| US201962946870P | 2019-12-11 | 2019-12-11 | |
| US202062956907P | 2020-01-03 | 2020-01-03 | |
| US202062956844P | 2020-01-03 | 2020-01-03 | |
| PCT/US2020/050459 WO2021050917A1 (en) | 2019-09-12 | 2020-09-11 | Phospholipid ether conjugates as cancer-targeting drug vehicles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291197A true IL291197A (en) | 2022-05-01 |
Family
ID=74866023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291197A IL291197A (en) | 2019-09-12 | 2022-03-08 | Phospholipid ether conjugates as vehicles for cancer-targeting drugs |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019200017A1 (en) * | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| MX2022003044A (es) * | 2019-09-12 | 2022-06-02 | Cellectar Biosciences Inc | Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. |
| KR102973364B1 (ko) * | 2019-10-10 | 2026-06-04 | 셀렉타 바이오사이언시스, 인코퍼레이티드 | 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 |
| CN113816990B (zh) * | 2021-03-22 | 2023-08-22 | 联宁（苏州）生物制药有限公司 | 修饰的氨基酸及其在adc中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8540968B2 (en) * | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| WO2011031919A2 (en) * | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Non-radioactive phospholipid compounds, compositions, and methods of use |
| CN107708702A (zh) * | 2014-11-17 | 2018-02-16 | 塞勒克塔生物科学有限公司 | 磷脂醚类似物作为靶向癌症的药物载体 |
| CN109310702A (zh) * | 2016-05-20 | 2019-02-05 | 芝加哥大学 | 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒 |
| CN109791152B (zh) * | 2016-06-14 | 2023-03-03 | 塞勒科塔生物科学公司 | 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物 |
| WO2019200017A1 (en) * | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| MX2022003044A (es) * | 2019-09-12 | 2022-06-02 | Cellectar Biosciences Inc | Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. |
-
2020
- 2020-09-11 MX MX2022003044A patent/MX2022003044A/es unknown
- 2020-09-11 US US17/642,561 patent/US20230066517A1/en active Pending
- 2020-09-11 JP JP2022516159A patent/JP7749542B2/ja active Active
- 2020-09-11 WO PCT/US2020/050459 patent/WO2021050917A1/en not_active Ceased
- 2020-09-11 CA CA3150991A patent/CA3150991A1/en active Pending
- 2020-09-11 BR BR112022004482A patent/BR112022004482A2/pt unknown
- 2020-09-11 AU AU2020346898A patent/AU2020346898B2/en active Active
- 2020-09-11 KR KR1020227011911A patent/KR20220062363A/ko active Pending
- 2020-09-11 EP EP20862948.5A patent/EP4028018A4/en active Pending
- 2020-09-11 CN CN202080074564.3A patent/CN114599371A/zh active Pending
-
2022
- 2022-03-08 IL IL291197A patent/IL291197A/en unknown
-
2025
- 2025-02-13 JP JP2025021639A patent/JP2025087716A/ja active Pending
- 2025-06-30 JP JP2025110172A patent/JP2025138792A/ja active Pending
-
2026
- 2026-06-11 AU AU2026204469A patent/AU2026204469A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020346898A1 (en) | 2022-04-07 |
| JP2025138792A (ja) | 2025-09-25 |
| JP2022547331A (ja) | 2022-11-11 |
| BR112022004482A2 (pt) | 2022-05-31 |
| AU2020346898B2 (en) | 2026-04-09 |
| CN114599371A (zh) | 2022-06-07 |
| JP7749542B2 (ja) | 2025-10-06 |
| AU2026204469A1 (en) | 2026-06-25 |
| WO2021050917A1 (en) | 2021-03-18 |
| EP4028018A1 (en) | 2022-07-20 |
| KR20220062363A (ko) | 2022-05-16 |
| MX2022003044A (es) | 2022-06-02 |
| JP2025087716A (ja) | 2025-06-10 |
| EP4028018A4 (en) | 2023-10-11 |
| NZ786360A (en) | 2025-12-19 |
| US20230066517A1 (en) | 2023-03-02 |
| CA3150991A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015350400B2 (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| TWI925817B (zh) | 抗體藥物結合物 | |
| IL274427A (en) | Hydrophilic linkers for drug-antibody conjugates | |
| CA3308359A1 (en) | Camptothecin conjugates | |
| IL291073A (en) | Drug conjugates of anti-egfr antibodies | |
| IL267834A (en) | Conjugates of drug and antibody against CCR7 | |
| AU2019247434A1 (en) | Camptothecin Peptide Conjugates | |
| EP3253212A4 (en) | Antibody drug conjugates | |
| EP3250238A4 (en) | Antibody drug conjugates | |
| EP3157560A4 (en) | Her2 antibody-drug conjugates | |
| EP3107557A4 (en) | Hydrophilic antibody-drug conjugates | |
| EP3086815A4 (en) | Sulfonamide-containing linkage systems for drug conjugates | |
| MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
| EP3129357A4 (en) | Affinity medicant conjugates | |
| EP3129047A4 (en) | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates | |
| EP2968600A4 (en) | Antibody drug conjugates | |
| EP3077006A4 (en) | Polymer-carbohydrate conjugates for drug delivery technology | |
| EP3538098A4 (en) | ANTIBODY-DRUG CONJUGATES | |
| MX2015012404A (es) | Formulaciones de citoquinas quimericas para suministro ocular. | |
| CA3252097A1 (en) | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP | |
| EP3980470A4 (en) | THREE-DIMENSIONAL PRINTING WITH TRIETHYLENE GLYCOL FUSION AGENTS | |
| HK40036495A (en) | Hydrophilic linkers for antibody drug conjugates | |
| HK40041699A (en) | Camptothecin conjugates | |
| HK40038979A (en) | Covalent anesthetic-polymer conjugates for prolonged local anesthesia | |
| HK40038453A (en) | Pyrrolobenzodiazepine antibody conjugates |